Combination therapy with HCV protease inhibitor, SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders.
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2009
At a glance
- Drugs Boceprevir; Peginterferon alfa-2b
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Schering-Plough
- 29 Oct 2009 Substudy results assesing antiretroviral resistance presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Dec 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History